Who is sponsoring NCT03694080?

NCT03694080 is sponsored by Zealand University Hospital.

What drugs are being tested in NCT03694080?

Interventions in NCT03694080: Calcium electroporation.

What condition does NCT03694080 study?

NCT03694080 studies Colorectal Cancer.

Is NCT03694080 still recruiting?

NCT03694080 is currently status unknown. Last updated 5 July 2019.

Last reviewed 2019-07-05 · How we verify

NCT03694080

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calcium Electroporation for Early Colorectal Cancer

Status unknown Phase 1 Last updated 5 July 2019

What this trial tests

Phase 1 trial testing Calcium electroporation in Colorectal Cancer in 24 participants. Status unknown.

Timeline

1 November 2018

Primary endpoint
1 May 2020

1 September 2020

Quick facts

Lead sponsor	Zealand University Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 November 2018
Primary completion	1 May 2020
Estimated completion	1 September 2020
Sites	1 location across Denmark

Drugs / interventions tested

Calcium electroporation — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Zealand University Hospital

Who can join

18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an explorative, phase I clinical trial. The aim of this study is to establish the safety and efficacy of treating patients with early colorectal cancer with calcium electroporation prior to intended curative surgery.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

A Comprehensive Review of Calcium Electroporation -A Novel Cancer Treatment Modality.
Frandsen SK, Vissing M, Gehl J. · · 2020 · cited 82× · PMID 31991784 · DOI 10.3390/cancers12020290
The Impact of Calcium Overload on Cellular Processes: Exploring Calcicoptosis and Its Therapeutic Potential in Cancer.
Gielecińska A, Kciuk M, Kontek R. · · 2024 · cited 23× · PMID 39769488 · DOI 10.3390/ijms252413727
In Vitro Study of Calcium Microsecond Electroporation of Prostate Adenocarcinoma Cells.
Kiełbik A, Szlasa W, Michel O, Szewczyk A, et al · · 2020 · cited 16× · PMID 33227916 · DOI 10.3390/molecules25225406
Palliative Treatment of Esophageal Cancer Using Calcium Electroporation.
Egeland C, Baeksgaard L, Gehl J, Gögenur I, et al · · 2022 · cited 14× · PMID 36358702 · DOI 10.3390/cancers14215283

Verify or expand the search:

Other trials of Calcium electroporation

Trials testing the same drug.

NCT05609656 — Electroporation and Immunotherapy in Metastatic Colorectal Cancer · Phase 2 · terminated
NCT04605419 — Calcium Electroporation in Patients With Cell Changes in the Esophagus · Phase 1 · unknown
NCT04259658 — Histopathologic Effect of Calcium Electroporation on Cancer in the Skin · Phase 2 · completed
NCT04225767 — Calcium Electroporation as a Treatment for Cutaneous and Subcutaneous Malignant Tumours · Phase 2 · unknown
NCT03542214 — Calcium Electroporation for the Treatment of Colorectal Cancer · Phase 1 · completed

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Zealand University Hospital trials

Trials by the same sponsor.

NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07365527 — Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03694080 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
Last refreshed: 5 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03694080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing